Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weight-Loss drug liraglutide tested in kids as young as 6

NCT ID NCT07590219

First seen May 16, 2026 · Last updated Jun 19, 2026 · Updated 9 times

Summary

This study tests whether the drug liraglutide, combined with healthy lifestyle changes, can help children aged 6 to 12 with severe obesity lose weight and improve heart function. Thirty children will receive either liraglutide injections plus lifestyle advice or lifestyle advice alone for 6 months. Researchers will measure changes in body mass index (BMI) and use advanced heart ultrasound to check for cardiovascular benefits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Childrens Institute - University of Sao Paulo

    São Paulo, São Paulo, 05403-000, Brazil

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

liraglutide (Saxenda)

What this could lead to

If it works, this could point toward a medication option to help severely obese children lose weight and improve heart health.

What could go wrong

This is a small, early-phase trial with only 30 children, so results may not apply broadly. Liraglutide can cause nausea, vomiting, and other side effects.

Conditions

The condition(s) this trial relates to.

morbid obesity Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.